Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $937.34 MXN
Change Today 0.00 / 0.00%
Volume 0.0
As of 4:09 PM 05/5/15 All times are local (Market data is delayed by at least 15 minutes).

teva pharmaceutical-sp adr (TEVAN) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/16/15 - $1,016
52 Week Low
05/16/14 - $638.00
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

teva pharmaceutical-sp adr (TEVAN) Details

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic, specialty, and other pharmaceutical products worldwide. The company operates in two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers generic or branded generic medicines; specialized products, such as sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances; and active pharmaceutical ingredients. The Specialty Medicines segment provides branded specialty medicines for use in central nervous system and respiratory indications, as well as the women’s health, oncology, and other specialty businesses. Its products in the central nervous system area comprise Copaxone for multiple sclerosis; Azilect for the treatment of Parkinson’s disease; Nuvigil and Provigil to treat excessive sleepiness associated with narcolepsy, obstructive sleep apnea, and shift work disorders; Fentora/Effentora and Actiq to treat pain in opioid-tolerant adult patients with cancer; Zecuity for the treatment of migraine in adults; and Amrix for muscle spasm in acute, painful, and musculoskeletal conditions. This segment’s products in the respiratory market include ProAir, QVAR, and Duoresp Spiromax for the treatment of asthma and chronic obstructive pulmonary disease, as well as Treanda, Trisenox, Granix, Synribo, Lonquex, Tevagrastim/Ratiograstim, Myocet, and Eporatio products in the oncology market. This segment also offers a portfolio of products in the women’s health category, which includes ParaGard, Plan B One-Step, and Zoely. In addition, the company provides branded over-the-counter medicines in the categories of cough/cold and allergy, digestive wellness, vitamins, minerals and supplements, analgesics, and skin medications; and sells third-party products, such as medical devices and other miscellaneous items. Teva Pharmaceutical Industries Limited was founded in 1901 and is headquartered in Petach Tikva, Israel.

43,009 Employees
Last Reported Date: 02/9/15
Founded in 1901

teva pharmaceutical-sp adr (TEVAN) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

teva pharmaceutical-sp adr (TEVAN) Key Developments

Teva Pharmaceutical Industries Limited Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Revises Earnings Guidance for the Year 2015; Reports Impairment Charges for the First Quarter Ended March 31, 2015

Teva Pharmaceutical Industries Limited reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported revenue of $4,982 million against $5,001 million a year ago. Operating income was $749 million against $972 million a year ago. Income before income taxes was $557 million against $891 million a year ago. Non-GAAP net profit was $1.36 per share against $1.23 per share a year ago, up 11% from the corresponding quarter. GAAP profit in the first quarter fell 40% to $0.52 per share. The figure was affected by exchange rate fluctuations, which lowered revenue by $368 million and adjusted operating income by $42 million. Excluding the currency impact and the sale of US over-the-counter plants, revenue increased 8%. Cash flow from operations generated amounted to $1.4 billion compared to $0.9 billion in the first quarter of 2014. The increase was mainly due to an increase in accounts payable and lower payments related to legal settlements in the first quarter of 2015. Free cash flow, excluding net capital expenditures, amounted to $1.2 billion, compared to $0.7 billion in the first quarter of 2014. Non-GAAP Operating income was $1,533 million against $1,381 million a year ago. Net income attributable to the company was $1,165 million against $1,051 million a year ago. The company has suggested that currency fluctuations led to a $368 million reduction in revenues. Diluted earnings per share attributable to the company were $0.52 against $0.87 a year ago. Non-GAAP diluted earnings per share attributable to the company were $1.36 against $1.23 a year ago. The company raised its earnings per share profit forecast for 2015 by $0.05. For the year 2015, the company expects earnings per share to be in the range of $5.05 to $5.35 against $5 to $5.30 expected earlier. The company’s revenues continue to remain flat, repeating a similar scenario for the full 2014 results. Alongside the flat revenues there has been a notable change in the mark-ups, with generic products now accounting for a bigger percentage of revenues than previously. For the quarter, the company reported impairment of long-lived assets of $65 million against $1 million a year ago.

Teva Pharmaceutical Industries Ltd. Declares Cash Dividend for the First Quarter of 2015, Payable on June 4, 2015

The board of directors of Teva Pharmaceutical Industries Ltd., at its meeting on April 28, 2015, declared a cash dividend for the first quarter of 2015 of $0.34. The record date will be May 19, 2015, and the payment date will be June 4, 2015.

Teva Pharmaceutical Industries Limited Launches Generic Abilify Tablets in the United States

Teva Pharmaceutical Industries Limited announced the launch of the generic equivalent to Abilify (aripiprazole) Tablets, 2 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg, in the United States. Aripiprazole tablets, an atypical antipsychotic medication, are approved for the treatment of schizophrenia and for the acute treatment of manic and mixed episodes associated with bipolar I disorder. Schizophrenia is a complex, long-term medical illness that affects a person's ability to think clearly, manage emotions, make decisions and relate to others. Approximately one percent of adult Americans live with schizophrenia. Schizophrenia is a chronic and disabling brain disorder that affects men and women equally, where people interpret reality abnormally. Symptoms of schizophrenia may include hallucinations, delusions, trouble with thinking and concentration, and lack of motivation. There are several types of bipolar disorder. Bipolar I disorder is a specific type of bipolar disorder characterized by manic or mixed episodes of feelings of extreme irritability or euphoria. Bipolar I disorder is the most severe form of the illness marked by extreme manic episodes. Aripiprazole tablets are indicated for: Treatment of schizophrenia in adults and adolescents (13 to 17 years of age). Acute treatment of manic and mixed episodes associated with bipolar I disorder as monotherapy and as adjunctive therapy to lithium or valproate in adults and pediatrics (10 to 17 years of age). Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Aripiprazole is not approved for the treatment of patients with dementia-related psychosis. Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term studies. In patients of all ages who are started on antidepressant therapy, monitor closely for worsening, and for emergence of suicidal thoughts and behaviors. Advise families and caregivers of the need for close observation and communication with the prescriber. Aripiprazole is contraindicated in patients with a history of a hypersensitivity reaction to aripiprazole. Reactions have ranged from pruritus/urticaria to anaphylaxis. A syndrome of potentially irreversible, involuntary, dyskinetic movements may develop in patients treated with antipsychotic drugs. If signs and symptoms of tardive dyskinesia appear in a patient on aripiprazole, drug discontinuation should be considered if clinically appropriate. Atypical antipsychotic drugs have been associated with metabolic changes that include hyperglycemia/diabetes mellitus, dyslipidemia, and body weight gain. Monitor glucose regularly in patients with and at risk for diabetes. Clinical monitoring of weight is recommended. Aripiprazole may cause orthostatic hypotension. Aripiprazole should be used with caution in patients with known cardiovascular disease, cerebrovascular disease, or conditions which would predispose patients to hypotension. Aripiprazole should be used cautiously in patients with a history of seizures or with conditions that lower the seizure threshold. Conditions that lower the seizure threshold may be more prevalent in a population of 65 years or older. Aripiprazole, like other antipsychotics, may have the potential to impair judgment, thinking, or motor skills. Patients should be cautioned about operating hazardous machinery, including automobiles, until they are reasonably certain that therapy with aripiprazole does not affect them adversely.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TEVAN:MM $937.34 MXN 0.00

TEVAN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $46.54 USD -0.31
AbbVie Inc $63.94 USD +0.08
Baxter International Inc $68.91 USD -0.74
Eli Lilly & Co $72.05 USD +0.14
Medtronic PLC $74.32 USD -0.59
View Industry Companies

Industry Analysis


Industry Average

Valuation TEVAN Industry Range
Price/Earnings 19.2x
Price/Sales 2.6x
Price/Book 2.3x
Price/Cash Flow 21.4x
TEV/Sales 2.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TEVA PHARMACEUTICAL-SP ADR, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at